A patient with Alzheimer's disease had their condition improve hugely just minutes after receiving a special injection of a prescription drug approved to treat psoriasis and rheumatoid arthritis and other conditions, according to a new study.
The drug, co-marketed in the U.S. by Amgen and Wyeth under the name Etanercept (Enbrel), dramatically reversed symptoms of an Alzheimer’s disease sufferer minutes after it was injected into the patient's spine, researchers in the U.S. discovered. The drug, sold in Australia as Etanercept, has also been used off-label for treating Alzheimer's.
Etanercept is a recombinant human soluble tumor necrosis factor-alpha (TNFα) receptor fusion protein. It is a large molecule, with a molecular weight of 150 kDa., that binds to TNFα and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFα.
A report on the new study appeared in the Journal of Neuroinflammation this week.
The drug, co-marketed in the U.S. by Amgen and Wyeth under the name Etanercept (Enbrel), dramatically reversed symptoms of an Alzheimer’s disease sufferer minutes after it was injected into the patient's spine, researchers in the U.S. discovered. The drug, sold in Australia as Etanercept, has also been used off-label for treating Alzheimer's.
Etanercept is a recombinant human soluble tumor necrosis factor-alpha (TNFα) receptor fusion protein. It is a large molecule, with a molecular weight of 150 kDa., that binds to TNFα and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFα.
A report on the new study appeared in the Journal of Neuroinflammation this week.
No comments:
Post a Comment